Optimizing Intensive Chemotherapy Management in Secondary AML Through Academic Community Collaboration

Margaret Kasner, MD, and Christian Fidler, MD, discuss how effective management of secondary acute myeloid leukemia (AML) in community settings requires early diagnosis, accurate risk stratification, timely referrals, personalized treatment approaches, robust supportive care, and close collaboration with academic centers to ensure optimal patient outcomes.

EP. 1: Implementing Updates to AML Classification Guidelines

October 18th 2024

Panelists discuss how secondary acute myeloid leukemia (AML) presents unique challenges in diagnosis, classification, and treatment due to its complex pathogenesis and evolving classification criteria.

EP. 2: Treatment Goals in Secondary AML

October 18th 2024

Panelists discuss how secondary acute myeloid leukemia (AML) generally carries a poorer prognosis compared to de novo AML, necessitating careful consideration of treatment goals and open communication with patients about their outlook.

EP. 3: The Role of Molecular and Cytogenetic Testing in Secondary AML

October 25th 2024

Panelists discuss how comprehensive molecular and cytogenetic testing at diagnosis is crucial for accurate risk stratification, treatment selection, and prognostication in secondary acute myeloid leukemia (AML), while acknowledging the challenges of obtaining timely results, especially in community settings.

EP. 4: Patient-Centered Decision-Making in Secondary AML Treatment

October 25th 2024

Panelists discuss how involving patients and caregivers in the treatment decision-making process for secondary acute myeloid leukemia (AML) requires clear communication, education about options, and consideration of individual values and preferences to ensure informed and shared decision-making.

EP. 5: Assessing Transplant Eligibility and Fitness for Intensive Chemotherapy

November 1st 2024

Panelists discuss how identifying candidates for allogeneic transplant in secondary acute myeloid leukemia involves a comprehensive assessment of disease characteristics, patient factors, and timing considerations, while also evaluating fitness for intensive chemotherapy induction using specific criteria to guide treatment decisions.

EP. 6: Evidence-Based Approaches to Intensive Chemotherapy in Secondary AML

November 1st 2024

Panelists discuss how the NCCN guidelines recommend intensive chemotherapy options, including traditional 7+3 and CPX-351, for newly diagnosed high-risk or secondary AML patients, with treatment selection based on individual patient factors and potential adverse effects.